Adding Retifanlimab To Chemotherapy Provides OS Benefit over Chemotherapy In First-Line Treatment of Patients with Advanced Squamous Anal Cancer By Ogkologos - May 18, 2026 10 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival analysis in the POD1UM-303/InterAACT-2 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Accelerated Approval to Sonrotoclax for Relapsed or Refractory Mantle Cell Lymphoma Ahead of key Competitiveness Council Meeting of European Research Ministers, ESMO calls for measures supporting a robust clinical research ecosystem in Europe that enables... EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib MOST POPULAR A career forged in team science March 10, 2023 Reduction Not Only in Recurrences, but Also in Mortality, Observed for... December 20, 2022 Cancer Research UK’s charity Christmas cards now available October 28, 2021 Gut Microbes May Influence How Well Radiation Therapy Works against Cancer September 2, 2021 Load more HOT NEWS Mouse Study Points to Strategy for Preserving Bone During Chemotherapy Mathew Knowles, Father Of Beyoncé, Fought And Beat Breast Cancer Abemaciclib Improves PFS at Six Months Among Patients with High-Grade Meningiomas... Tarlatamab Shows Promise in Patients with Previously Treated Small-Cell Lung Cancer
